Schizophrenia Patients Who Used Cannabis Actually Had Better Cognitive Function Than Non-Users

A meta-analysis of 10 studies plus new first-episode data found that schizophrenia patients with a history of cannabis use performed better on cognitive tests than non-using patients, possibly because they needed less cognitive vulnerability to develop psychosis.

Yücel, Murat et al.·Schizophrenia bulletin·2012·Strong EvidenceMeta-Analysis
RTHC-00639Meta AnalysisStrong Evidence2012RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
Strong Evidence
Sample
N=572

What This Study Found

In a surprising finding that contradicts common assumptions, the meta-analysis of 572 patients found that those with a history of cannabis use had superior neuropsychological functioning compared to non-using schizophrenia patients. This was primarily driven by studies including patients with lifetime (rather than current) cannabis history.

A second study of 85 first-episode psychosis (FEP) patients confirmed the pattern: cannabis-using FEP patients showed only selective cognitive impairments while non-users showed generalized deficits. Cannabis users performed better on visual memory, working memory, and executive functioning. Patients who started cannabis earlier had even less cognitive impairment.

Key Numbers

Meta-analysis: 10 studies, 572 patients. FEP study: 59 cannabis users vs. 26 non-users vs. 43 controls. Cannabis users outperformed non-users on visual memory, working memory, and executive functioning. Earlier cannabis onset associated with less cognitive impairment.

How They Did This

Two-part study. Study I: Meta-analysis of 10 studies comprising 572 patients with established schizophrenia. Study II: Neuropsychological testing of 85 first-episode psychosis patients (59 cannabis users, 26 non-users) and 43 healthy controls.

Why This Research Matters

This counterintuitive finding has an important implication: cannabis-using patients who develop psychosis may represent a "cognitively less impaired" subgroup who needed an environmental trigger (cannabis) to develop psychosis. Non-using patients may have developed psychosis due to greater underlying cognitive vulnerability, without needing an external trigger.

The Bigger Picture

This research reshapes understanding of the cannabis-psychosis relationship. Rather than cannabis universally worsening cognitive outcomes in psychosis, it appears that the people who develop psychosis after cannabis use may be fundamentally different, cognitively stronger, than those who develop it without cannabis exposure.

What This Study Doesn't Tell Us

The meta-analysis included mostly cross-sectional studies. Better cognition in cannabis users could reflect selection bias (more cognitively intact people are more likely to access and use cannabis). Lifetime cannabis history includes people who stopped years ago. The sample sizes, while reasonable for a meta-analysis, are modest.

Questions This Raises

  • ?Does the cognitive advantage of cannabis-using patients persist over the long term?
  • ?Does this finding change how cannabis-using psychosis patients should be treated?
  • ?Could cognitive testing help predict which cannabis users are at genuine psychosis risk?

Trust & Context

Key Stat:
Cannabis-using psychosis patients outperformed non-users on working memory and executive function
Evidence Grade:
Meta-analysis of 10 studies plus a new first-episode sample; strong evidence for the cognitive difference, though causation remains unclear.
Study Age:
Published in 2012. The "neurocognitively less impaired" hypothesis for cannabis-using psychosis patients has been further investigated since.
Original Title:
The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.
Published In:
Schizophrenia bulletin, 38(2), 316-30 (2012)
Database ID:
RTHC-00639

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Frequently Asked Questions

How can cannabis users with psychosis have better cognition?

The leading explanation is that cannabis-using psychosis patients started with better baseline cognitive function. They may have needed the additional risk from cannabis to push them into psychosis, whereas non-using patients had enough underlying vulnerability to develop psychosis without any environmental trigger. Cannabis use in this model is a marker of less inherent vulnerability, not a cause of better cognition.

Does this mean cannabis is good for people with schizophrenia?

No. The study does not show that cannabis improves cognition in schizophrenia. Rather, it suggests that people who develop psychosis after cannabis use may represent a distinct subgroup with better baseline cognitive abilities. Cannabis use in schizophrenia is still associated with poor treatment compliance and psychotic relapse.

Read More on RethinkTHC

Cite This Study

RTHC-00639·https://rethinkthc.com/research/RTHC-00639

APA

Yücel, Murat; Bora, Emre; Lubman, Dan I; Solowij, Nadia; Brewer, Warrick J; Cotton, Sue M; Conus, Philippe; Takagi, Michael J; Fornito, Alex; Wood, Stephen J; McGorry, Patrick D; Pantelis, Christos. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.. Schizophrenia bulletin, 38(2), 316-30. https://doi.org/10.1093/schbul/sbq079

MLA

Yücel, Murat, et al. "The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.." Schizophrenia bulletin, 2012. https://doi.org/10.1093/schbul/sbq079

RethinkTHC

RethinkTHC Research Database. "The impact of cannabis use on cognitive functioning in patie..." RTHC-00639. Retrieved from https://rethinkthc.com/research/yucel-2012-the-impact-of-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.